Subscribe to our Newsletters !!

    pharma business

    Wockhardt accomplices with UK govt for COVID-19 vaccines

    Drug firm Wockhardt on Monday said it has entered into an agreement with the UK authorities to fill-finish COVID-19 vaccines, and will tackle manufacturing in its centre in North Wales. The manufacturing will be undertaken at CP Pharmaceuticals, a subsidiary of the firm based in North Wales, Wockhardt said in a statement. As per the

    Dr Reddy’s’ settles case with Bristol Myers Squibb unit over nonexclusive malignant growth drug

    The Hyderabad-based firm has settled litigation with Celgene, a wholly-owned subsidiary of Bristol Myers Squibb, Dr Reddy”s Laboratories said in a statement. In settlement of all outstanding claims in the litigation, Celgene has agreed to provide the company with a permit to sell volume-limited amounts of generic lenalidomide capsules in america starting on a confidential

    Zydus Cadila gets USFDA gesture for numerous sclerosis treatment drug

    Zydus Cadila has received final approval from the United States Food and Drug Administration (USFDA) to market Dimethyl Fumarate delayed release capsules, (Tecfidera) in the strengths of 120 mg and 240 mg, Zydus Cadila, part of Cadila Healthcare group, said in a regulatory filing. Zydus Cadila said in its approval, the USFDA noted that Zydus

    New Particle Analysis module introduced by Renishaw

    The module simplifies the inVia microscope so that it can identify particles on pictures and then analyse them using Raman spectroscopy. Renishaw’s inVia Raman system has a high quality microscope that’s great for producing optical images of particles on surfaces. These images are utilized to direct Raman spectroscopy measurements that quickly give chemically specific, high

    Cipla launches Nintib to treat Idiopathic Pulmonary Fibrosis

    Mumbai, India; October 20, 2020: Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and hereafter referred to as “Cipla”) today announced that it has launched generic Nintedanib for the treatment of Idiopathic Pulmonary Fibrosis (IPF). Available as 100 mg and 150 mg capsules, it will be marketed under the brand name Nintib. This launch marks yet

    Lupin, Concord Biotech get USFDA gesture for generic immunosuppressant cases

    New Delhi, Nov 12 (PTI) Drug firm Lupin on Thursday stated that in alliance with Concord Biotech, it has obtained acceptance from the US health regulator to market generic immunosuppressant Tacrolimus capsules used in the Western industry. In cooperation with Concord Biotech, the business has obtained approval from the United States Food and Drug Administration


    New Delhi: Drug important Glenmark Pharma on Thursday said it has received final approval from the US health regulator for Tadalafil tablets, used to treat erectile dysfunction and enlarged prostate. The business also received two tentative approvals in the US health regulator. Glenmark Pharmaceuticals Ltd has received final approval from the United States Food and

    Strides Pharma gets USFDA endorsement for Prednisone tablets

    New Delhi: Drug company Strides Pharma Science on Friday said its subsidiary, Strides Pharma International Pte Ltd, has received approval from the US health regulator for Prednisone pills , prescribed for a variety of conditions, such as allergies, respiratory disease and arthritis. Strides Pharma Global Pte Limited, Singapore, has obtained approval for Prednisone tablets USP

    Aurobindo Pharma gets USFDA gesture for conventional Droxidopa capsules

    New Delhi: Drug major Aurobindo Pharma on Friday said it has received final approval from the US health regulator to manufacture and market Droxidopa capsules, used to treat dizziness and lightheadedness. The approved product is a generic version of Lundbeck NA Ltd’s Northera capsules. The business has received final approval from the US Food and

    Alembic Pharma gets USFDA gesture for bipolar depression drug

    New Delhi, May 14 (PTI) Drug firm Alembic Pharmaceuticals on Friday said it has received final approval from the US health regulator for Lurasidone Hydrochloride tablets, used to treat bipolar depression. The approved product is therapeutically equivalent to the reference listed drug product (RLD) Latuda tablets of Sunovion Pharmaceuticals Inc. The company has received approval